Welcome to our dedicated page for 60 Degrees Pharmaceuticals news (Ticker: SXTP), a resource for investors and traders seeking the latest updates and insights on 60 Degrees Pharmaceuticals stock.
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) is a specialty pharmaceutical company focused on the development and commercialization of new therapies for the prevention and treatment of infectious diseases. Founded in 2010 and headquartered in Washington D.C., the company leverages biological science and applied research to combat various viral, fungal, and tick-borne diseases.
60 Degrees Pharmaceuticals' flagship product, ARAKODA® (tafenoquine), received FDA approval in 2018 for malaria prophylaxis in patients aged 18 years and older. ARAKODA® is also approved in Australia under the name KODATEF® and was launched commercially in both countries in 2019. It is available through pharmaceutical wholesaler networks and retail pharmacies as a prescription-only medication. The drug's long terminal half-life, approximately 16 days, offers potential advantages in reducing the frequency of doses required for malaria prevention.
Currently, the company is expanding its research scope to include other indications for tafenoquine, notably the treatment of acute babesiosis, a tick-borne disease. The U.S. Food and Drug Administration (FDA) recently granted orphan drug designation to tafenoquine for this purpose. This designation provides 60 Degrees Pharmaceuticals with various incentives, including market exclusivity, tax credits, and fee exemptions.
In addition to its work on babesiosis, the company is developing treatment options for COVID-19 and other infectious diseases. This includes a pilot study to evaluate the efficacy of tafenoquine in treating canine babesiosis, conducted in collaboration with North Carolina State University.
60 Degrees Pharmaceuticals continues to collaborate with prominent research organizations in the U.S., Australia, and Singapore. The company's research and development efforts have received in-kind support from the U.S. Department of Defense and private institutional investors like Knight Therapeutics Inc. The firm remains committed to advancing its pipeline products and supporting clinical trials that could significantly impact public health.
For more information about their products, ongoing trials, and latest news updates, visit www.60degreespharma.com.
FAQ
What is the current stock price of 60 Degrees Pharmaceuticals (SXTP)?
What is the market cap of 60 Degrees Pharmaceuticals (SXTP)?
What does 60 Degrees Pharmaceuticals specialize in?
What is ARAKODA®?
What recent achievements has 60 Degrees Pharmaceuticals made?
What are the current projects of 60 Degrees Pharmaceuticals?
Who are 60 Degrees Pharmaceuticals' key collaborators?
Where is 60 Degrees Pharmaceuticals headquartered?
How can I get more information about ARAKODA®?
Is tafenoquine approved for treating babesiosis?
How is 60 Degrees Pharmaceuticals funded?
How can I stay updated on the latest news from 60 Degrees Pharmaceuticals?
